Persistent anemia in some patients with CKD may reflect an inflammation-driven biology, with the IL-6–hepcidin axis linking iron restriction to impaired erythropoiesis.
The future of FGF21 in MASH will depend on delivering meaningful and durable liver and fibrosis benefits beyond weight loss alone.
Innovation creates opportunity, but disciplined development, global positioning, and the right partnerships are what turn promising biotech assets into lasting value.
All Presentations
- Why Is CKD-Associated Anemia Still an Unmet Need?Featured
- FGF21 in MASH: From Pathway Validation to a Differentiated Therapeutic ProductFeatured
- Beyond Innovation: Realizing the Full Potential of China’s Emerging Biotech AssetsFeatured
- 超越创新：让中国新兴Biotech资产真正实现价值
- Beyond Reperfusion: Enhancing Endogenous Neurovascular Repair to Improve Long-Term Recovery After Stroke
- Beyond FVC: What Will Define the Next Generation of IPF Therapies?
- More Receptors, Better Therapy? Defining the Long-Term Value of Next-Generation Incretin-Based Therapies
- The Real Promise of Longevity Medicine Is Coming Into Focus